Welcome to The Age-Related Eye Disease Study 2 (AREDS2) was a multi-center, randomized trial designed to assess the effects of oral. The Age-Related Eye Disease Study 2 (AREDS2) Research Group* . AREDS2 was designed to test whether adding lutein + zeaxanthin, DHA. Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The Age-Related Eye Disease Study 2 (AREDS2).

Author: Tygorn Dishakar
Country: Fiji
Language: English (Spanish)
Genre: Sex
Published (Last): 1 May 2005
Pages: 20
PDF File Size: 13.25 Mb
ePub File Size: 14.65 Mb
ISBN: 442-7-13347-708-5
Downloads: 43773
Price: Free* [*Free Regsitration Required]
Uploader: Maujar

Xreds2 of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Participants lost to follow-up or who died during the course of the study were censored at the time of last contact. The distribution of the visual acuity for study and non-study eyes by visual acuity category is provided in Table 5. Information on AMD treatment and adverse effects was arrds2 by telephone and at annual visits.

A computerized method of visual acuity testing: Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: Cigarette smoking, fish consumption, omega-3 arede2 acid intake, and associations with age-related macular degeneration: Dietary carotenoids, vitamins C and E, and risk of cataract in women: All participants were randomly assigned to: Methods All participants were randomly assigned to: Analysis and interpretation of data: Create a free personal account to download free article PDFs, sign up for alerts, customize your interests, and more.

Masked graders at a central reading center used a standard protocol to assess qreds2 photographs. Telephone contacts are primarily used to collect information about adverse events.

Docosahexaenoic acid is required for the survival of rat retinal photoreceptors in vitro.

AREDS2 Results Released

Of the remaining sfudy, The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. J Natl Cancer Inst. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.


Main Effects of Aeds2 Randomization. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. The primary purpose of the study is a comparison of the three active treatment arms to placebo on progression to advanced AMD based on reading center grading of color stereoscopic fundus photographs in study eyes.

Arers2, these results will be clinically important for most persons who are at risk for developing AMD.

Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. This formulation was given as a mixture of antioxidant vitamins and minerals. Epping Education session VIC: Arrds2 randomized controlled clinical trial is designed to evaluate the role of macular xanthophylls and omega-3 LCPUFAs on the progression of age-related macular degeneration and, secondarily, progression of cataract.

Age-Related Eye Disease Study 2 (AREDS2) | National Eye Institute

Adherence to the treatment regimen was assessed by pill count at each annual visit. Create a free personal account to make a comment, download free article PDFs, sign up for alerts and more.

Lutein prevents cataract development and progression in diabetic rats. Rates of reported gastrointestinal disorders and hospitalizations stuvy genitourinary diseases were similar in the 2 randomly assigned groups high-dose zinc, low-dose zinc in AREDS2. Am J Clin Nutr. Lutein and zeaxanthin are the only carotenoids detected in the human lens.

If a benefit could be demonstrated, it was therefore likely to be important. The primary outcome was the development of stidy AMD, defined as central geographic atrophy or retinal features of choroidal neovascularization detected on central grading of the stereoscopic fundus photographs or a history of treatment for advanced AMD after study enrollment.

The analysis will be similar to the analyses described above using a time-based outcome of progression to moderate vision loss. All participants were also asked to take the original AREDS formulation or accept a secondary randomization to 4 variations of the AREDS formulation, including elimination of beta carotene, lowering of zinc dose, or both.


The unit of analysis for ophthalmic outcomes was by eye.

AREDS2 Results Released | Macular Disease Foundation Australia

Inclusion and exclusion criteria have been published. Lutein and zeaxanthin and the risk of cataract: The baseline serum levels of study nutrients were balanced across the treatment groups; the levels achieved during the study are reported in eTables Create a personal account to register for email alerts with links to free full-text articles.

The number of lung cancers ateds2 small, and the analyses of competing risk showed essentially no change in our mortality results.

Previous dose-ranging studies provided support for the doses used.

No other authors reported disclosures. To compute the necessary sample size, adjustments were made for projected deaths and losses to stuxy. Dobbing J, Benson JD, editors.

Sign in to download free article PDFs Sign in to access your subscriptions Sign in to your personal account. Institutional review boards approved the AREDS2 research protocol, and all participants provided written informed consent.

At baseline arsds2 at each annual study visit, participants received a comprehensive eye exam including best-corrected visual acuity obtained with the electronic version of the ETDRS visual acuity charts. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: Likelihood of adherence to the study regimen was evaluated during a run-in phase using study placebo and the AREDS formulation.